Can drug repurposing strategies be the solution to the COVID-19 crisis?

References

• World Health Organization. WHO coronavirus disease (COVID-19) dashboard. [ cited October 10th 2020]. Available from: https://covid19.who.int/
   Google Scholar
• Nicola M, Alsafi Z, Sohrabi C, et al. The socio-economic implications of the coronavirus pandemic (COVID-19): A review. Int J Surg. 2020;78:185–193.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Coronavirus Treatment Acceleration Program (CTAP). [ cited October 10th 2020]. Available from: https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap
   Google Scholar
• Chodera J, Lee AA, London N, et al. Crowdsourcing drug discovery for pandemics. Nat Chem. 2020;12:581.
   PubMed Web of Science ®Google Scholar
• Chesbrough H. To recover faster from Covid-19, open up: managerial implications from an open innovation perspective. Ind Mark Manag. 2020;88:410–413.
   Web of Science ®Google Scholar
• Islam MT, Nasiruddin M, Khan IN, et al. Perspective on emerging therapeutic interventions for COVID-19. Front Public Health. 2020;8:281.
   PubMed Web of Science ®Google Scholar
• Sarkar C, Mondal M, Islam MT, et al. Potential therapeutic options for COVID-19: current status, challenges, and future perspectives. Front Pharmacol. 2020;11. DOI:10.3389/fphar.2020.572870
   PubMed Web of Science ®Google Scholar
• Naylor S, Kauppi DM, Schonfeld JP. Therapeutic drug repurposing, repositioning and rescue part II: business review. Drug Discovery World. 2015;16(2):57–72.
   Google Scholar
• Naylor S, Kauppi DM, Schonfeld JP. Therapeutic drug repurposing, repositioning and rescue: part III: market exclusivity using intellectual property and regulatory pathways. Drug Discovery World. 2015;16(3):62–69.
   Google Scholar
• Oprea TI, Overington JP. Computational and practical aspects of drug repositioning. Assay Drug Dev Technol. 2015;13(6):299–306.
   PubMed Web of Science ®Google Scholar
• Pantziarka P, Bouche G, Meheus L, et al. The repurposing drugs in oncology (ReDO) project. Ecancermedicalscience. 2014;8:442.
   PubMedGoogle Scholar
• World Health Organization. WHO target product profiles for COVID-19 therapeutics. 2020. [cited October 10th 2020]. Available from: https://www.who.int/publications/m/item/who-target-product-profiles-for-covid-19-therapeutics.
   Google Scholar
• Breckenridge A, Jacob R. Overcoming the legal and regulatory barriers to drug repurposing. Nat Rev. 2019;8:1–2.
   Google Scholar
• Talevi A, Bellera CL. Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics. Expert Opin Drug Discov. 2020;15:397–401.
   PubMed Web of Science ®Google Scholar
• Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18:41–58.
   PubMed Web of Science ®Google Scholar
• Chaudhuri S, Symons JA, Deval J. Innovation and trends in the development and approval of antiviral medicines: 1987-2017 and beyond. Antiviral Res. 2018l;155:76–88.
   PubMed Web of Science ®Google Scholar
• Forum of International Respiratory Societies. The global impact of respiratory disease. Second ed. Sheffield: European Respiratory Society; 2017.
   Google Scholar
• Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19:149–150.
   PubMed Web of Science ®Google Scholar
• Pooladanda V, Thatikonda S, Godugu C. The current understanding and potential therapeutic options to combat COVID-19. Life Sci. 2020;254:117765.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020 May 16;395(10236):1569–1578. Erratum in: Lancet. 2020 May 30;395(10238):1694.
   PubMed Web of Science ®Google Scholar
• Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395:1695–1704.
   PubMed Web of Science ®Google Scholar
• Davoudi-Monfared E, Rahmani H, Khalili H, et al. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrob Agents Chemother. 2020;64:e01061–20.
   PubMed Web of Science ®Google Scholar
• Ramiro S, Mostard RLM, Magro-Checa C, et al. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study. Ann Rheum Dis. 2020;79(9):1143–1151.
   PubMed Web of Science ®Google Scholar
• Maskin LP, Olarte GL, Jr PF, et al. High dose dexamethasone treatment for Acute respiratory distress syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21:743.
   PubMedGoogle Scholar
• Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56:105949.
   PubMed Web of Science ®Google Scholar
• Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;3:104787.
   Google Scholar
• Omura S, Crump A. Ivermectin: panacea for resource-poor communities? Trends Parasitol. 2014;30:445–455.
   PubMed Web of Science ®Google Scholar
• Yang SNY, Atkinson SC, Wang C, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral Res. 2020;177:104760.
   PubMed Web of Science ®Google Scholar
• Chaccour C, Hammann F, Ramón-García S, et al. Ivermectin and COVID-19: keeping rigor in times of urgency. Am J Trop Med Hyg. 2020;102:1156–1157.
   PubMed Web of Science ®Google Scholar
• Pan H, Peto R, Abdool Karim Q, et al., WHO, Solidarity trial consortium. As the members of the writing committee. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. medRxiv. 2020;10:15.20209817.
   Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. ACTT-1 study group members. remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383:1813–1826.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA approves first treatment for COVID-19. [cited October 10th 2020]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19
   Google Scholar
• Wang N, Zhan Y, Zhu L, et al. Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients. Cell Host Microbe. 2020;28:455–464.
   PubMed Web of Science ®Google Scholar
• Collaborative Group RECOVERY, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med. 2020 Jul 17;NEJMoa2021436.
   Web of Science ®Google Scholar
• Jans DA, Wagstaff KM. Ivermectin as a broad-spectrum host-directed antiviral: the real deal? Cells. 2020;9:2100.
   Web of Science ®Google Scholar
• Shin D, Mukherjee R, Grewe D, et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature. 2020;(in press). doi:10.1038/s41586-020-2601-5.
   Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280.
   PubMed Web of Science ®Google Scholar
• Cantuti-Castelvetri L, Ojha R, Pedro LD, et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science. 2020;370:eabd2985.
   Web of Science ®Google Scholar
• Sternitzke C. Drug repurposing and the prior art patents of competitors. Drug Discov Today. 2014;19:1841–1847.
   PubMed Web of Science ®Google Scholar
• Gurry F Intellectual property, innovation, access and COVID-19. WIPO magazine 2020. [ cited 2020 Oct 7th]. Available from: https://www.wipo.int/wipo_magazine/en/2020/02/article_0002.html.
   Google Scholar
• Nicol D, Nielsen J Humanity cannot afford a COVID‑19 patent battle. [ cited 2020 Oct 7th]. Available from: https://www.science.org.au/curious/policy-features/humanity-cannot-afford-covid-19-patent-battle
   Google Scholar
• Contreras JL, Eisen M, Peters DMCOVID-19 save lives with open intellectual-property licences. Nature. 2020;583:683.
   PubMed Web of Science ®Google Scholar
• Wong H. The case for compulsory licensing during COVID-19. J Glob Health. 2020;10:010358.
   PubMed Web of Science ®Google Scholar
• Hoen E. Protect against market exclusivity in the fight against COVID-19. Nat Med. 2020;26:813.
   PubMed Web of Science ®Google Scholar
• Allarakhia M. Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases. Drug Des Devel Ther. 2013;7:753–766.
   PubMed Web of Science ®Google Scholar
• Thompson DC, Bentzien J. Crowdsourcing and open innovation in drug discovery: recent contributions and future directions. Drug Discov Today. 2020;25(In press):2284–2293.
   PubMedGoogle Scholar
• Ullrich S, Nitsche C. The SARS-CoV-2 main protease as drug target. Bioorg Med Chem Lett. 2020;30:127377.
   PubMed Web of Science ®Google Scholar
• Khanjiwala Z, Khale A, Prabhu A. Docking structurally similar analogues: dealing with the false-positive. J Mol Graph Model. 2019;93:107451.
   PubMed Web of Science ®Google Scholar
• Deng N, Forli S, He P, et al. Distinguishing binders from false positives by free energy calculations: fragment screening against the flap site of HIV protease. J Phys Chem B. 2015;119:976–988.
   PubMed Web of Science ®Google Scholar
• Adeshina YO, Deeds EJ, Karanicolas J. Machine learning classification can reduce false positives in structure-based virtual screening. Proc Natl Acad Sci USA. 2020;117:18477–18488.
   PubMed Web of Science ®Google Scholar
• Gushchina IV, Polenova AM, Suplatov DA, et al. vsFilt: A tool to improve virtual screening by structural filtration of docking poses. J Chem Inf Model. 2020;60:3692–3696.
   PubMed Web of Science ®Google Scholar
• Ye WL, Shen C, Xiong GL, et al. Improving docking-based virtual screening ability by integrating multiple energy auxiliary terms from molecular docking scoring. J Chem Inf Model. 2020;60:4216–4230.
   PubMed Web of Science ®Google Scholar
• My TTA, Loan HTP, Hai NTT, et al. Evaluation of the inhibitory activities of COVID-19 of Melaleuca cajuputi oil using docking simulation. Chem Sel. 2020;5:6312–6320.
   Google Scholar
• Alexpandi R, De Mesquita JF, Pandian SK, et al. Quinolines-based SARS-CoV-2 3CLpro and RdRpinhibitors and spike-RBD-ACE2 inhibitor for drug-repurposing against COVID-19: an in silico analysis. Front Microbiol. 2020;11:1796.
   PubMed Web of Science ®Google Scholar
• Tariq A, Mateen RM, Afzal MS, et al. A potential dual targeted drug effectively inhibits both spike (S1) and main protease of COVID-19. Int J Infect Dis. 2020;98:166–175.
   PubMed Web of Science ®Google Scholar
• Cohen J, Kupferschmidt K. The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug. Science. 2020;370:642–643.
   PubMed Web of Science ®Google Scholar
• Riva L, Yuan S, Yin X, et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020;586:113–119.
   PubMed Web of Science ®Google Scholar
• Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586:516–527.
   PubMed Web of Science ®Google Scholar
• Tseng CT, Sbrana E, Iwata-Yoshikawa N, et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS ONE. 2012;7:e35421.
   PubMed Web of Science ®Google Scholar
• Bolles M, Deming D, Long K, et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol. 2011;85:12201–12205.
   PubMed Web of Science ®Google Scholar
• Scott FW. Evaluation of risks and benefits associated with vaccination against coronavirus infections in cats. Adv Vet Med. 1999;41:347–358.
   PubMedGoogle Scholar
• Oroojalian F, Haghbin A, Baradaran B, et al. Novel insights into the treatment of SARS-CoV-2 infection: an overview of current clinical trials. Int J Biol Macromol. 2020 Dec 15;165(PtA):18–43. Epub 2020 Sep 28. PMID: 32991900; PMCID: PMC7521454.
   PubMedGoogle Scholar